MAY 29, 2026 AT 12:19 PM

Johnson & Johnson (JNJ) announces US FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma

Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.

Open Dashboard

#JOHNSON & JOHNSON#JNJ.US#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES

External